The new definition and diagnostic criteria of Parkinson's disease

Ronald B. Postuma; Daniela Berg; Charles H. Adler; Bastiaan R. Bloem; Piu Chan; Günther Deuschl; Thomas Gasser; Christopher G. Goetz; Glenda Halliday; Lawrence Joseph; Anthony E. Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; Wolfgang Oertel; C. Warren Olanow; Werner Poewe; Matthew Stern

doi:10.1016/S1474-4422(16)00116-2

The new definition and diagnostic criteria of Parkinson's disease

Ronald B. Postuma, Daniela Berg, Charles H. Adler, Bastiaan R. Bloem, Piu Chan, Günther Deuschl, Thomas Gasser, Christopher G. Goetz, Glenda Halliday, Lawrence Joseph, Anthony E. Lang, Inga Liepelt-Scarfone, Irene Litvan, Kenneth Marek, Wolfgang Oertel, C. Warren Olanow, Werner Poewe, Matthew Stern

Research output: Contribution to journal › Letter › peer-review

88 Scopus citations

Original language	English
Pages (from-to)	546-548
Number of pages	3
Journal	The Lancet Neurology
Volume	15
Issue number	6
DOIs	https://doi.org/10.1016/S1474-4422(16)00116-2
State	Published - 1 May 2016

Access to Document

10.1016/S1474-4422(16)00116-2

Cite this

Postuma, R. B., Berg, D., Adler, C. H., Bloem, B. R., Chan, P., Deuschl, G., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., Lang, A. E., Liepelt-Scarfone, I., Litvan, I., Marek, K., Oertel, W., Olanow, C. W., Poewe, W., & Stern, M. (2016). The new definition and diagnostic criteria of Parkinson's disease. The Lancet Neurology, 15(6), 546-548. https://doi.org/10.1016/S1474-4422(16)00116-2

@article{f1243d4a01d14b91ab0c1c6d48438be4,

title = "The new definition and diagnostic criteria of Parkinson's disease",

author = "Postuma, {Ronald B.} and Daniela Berg and Adler, {Charles H.} and Bloem, {Bastiaan R.} and Piu Chan and G{\"u}nther Deuschl and Thomas Gasser and Goetz, {Christopher G.} and Glenda Halliday and Lawrence Joseph and Lang, {Anthony E.} and Inga Liepelt-Scarfone and Irene Litvan and Kenneth Marek and Wolfgang Oertel and Olanow, {C. Warren} and Werner Poewe and Matthew Stern",

note = "Funding Information: DB received funds for consultancy/speaking from UCB pharma, Teva, Novartis, and Lundbeck; and grants from the Michael J Fox Foundation, Janssen Pharmaceuticals, the German Parkinsons' disease Association, Parkinson Fonds Deutschland, Teva, and the European Union. RBP received grants from the Fonds de la Recherche en Sante Quebec, the Canadian Institute of Health Research, the Parkinson Society of Canada, the Weston-Garfield Foundation, the Michael J Fox foundation, and the Webster Foundation; funding for consultancy from Biotie and Roche; and speaker fees from Novartis Canada and Teva Neurosciences. CHA has received research funding from Phytopharm, Avid Radiopharmaceuticals, the Michael J Fox Foundation, the National Institutes of Health, US Department of Defense, and the Arizona Biomedical Research Foundation; and consulting fees from Abbvie, Acadia, Allergan, Impax, Ipsen, Lily, Lundbeck, Merz, Novartis, Teva, and Xenoport. BRB received grant funding from the Netherlands Organization for Scientific Research, Prinses Beatrix Foundation, Stichting Parkinson Fonds, Michael J Fox Foundation, Parkinson Vereniging, and the National Parkinson Foundation; and consultancy/speaker fees from Danone, Zambon, Abbvie, and Teva. PC received grant support from the Ministry of Science and Technology of China. CGG received funds for consultancy from Acadia (Deborah Wood Associates), AstraZeneca, Avanir, Boston Scientific, Ceregene, Clearview, Health Advances, Chelsea Pharmaceuticals (Link Medical Communications), ICON Pricespective LLC, Med-IQ Educational Services, Neurocrine, Pfizer, Pricespective, Teva, and WPP Group Kantor Health LLC; royalties from Oxford University Press, Elsevier Publishers, Wolters Kluwer Health-Lippincott, and Wilkins and Wilkins; grant support from National Institutes of Health, Michael J Fox Foundation, and the Movement Disorders Society; travel support from Ceregene; and is a board member for Acadia and AstraZeneca. CGG directs the Rush Parkinson's Disease Research Center that receives support from the Parkinson's Disease Foundation; he directs the translation programme for the Movement Disorder Society Unified Parkinson's Disease Rating Scale and the Unified Dyskinesia Rating Scale and receives funds from the International Parkinson and Movement Disorder Society for this effort. GH has stock ownership in Cochlear and NIB Holdings; has received consultancy funds from the National Health and Research Council, has received royalties from Academic press, Elsevier, and Oxford University Press; and has grants from National Health and Research Council, Michael J Fox Foundation, Shake-it-Up Australia, Parkinson's NSW, and University of New South Wales. AEL received consultancy from Novartis, Teva, Abbott, Allon Therapeutics, Avanir Pharmaceuticals, Merck, Medtronic, AbbVie, Biogen Idec, Boehringer Ingelheim, NeuroPhage Pharmaceuticals, Centogene, Ceregene; expert testimony regarding welding rods; has grants/grants pending with Canadian Institutes of Health Research, Michael J Fox Foundation, National Parkinson Foundation, Brain Canada, W Garfield Weston Foundation, Parkinson Society Canada, Tourette Syndrome Association, Edmond J Safra Philanthropic Foundation, and Ontario Brain Institute; and has royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press. IL has served on advisory boards for Pfizer, Teva Neuroscience, Merz pharmaceuticals, Northera, Bristol-Myers Squibb, and has been a consultant for UCB pharma; she has received grants the National Institute of Health, the Parkinson Study Group, the Michael J Fox Foundation, CBD solutions-CurePSP, Teva Pharmaceuticals, and AVID Pharmaceuticals. KM received consultancy from Molecular Imaging, Pfizer, GE Healthcare, Merck, Lilly, Bristol-Myers Squibb, Piramal, Prothena, Roche, Oxford Biomedica, Lysosomal Therapeutic. WO is Senior Research Professor of the Charitable Hertie Foundation, Frankfurt/Main Germany. CWO received consultancy from Abbvie, Lilly/Medtronic, LUndbeck, Newron, Novartis, Teva, and Zambon, and owns stock in Clintrex, and has grant support from the Michael J Fox Foundation, the National Space Board Research Institute, and Zambon. WP received personal fees from Abbvie, Allergan, Astra Zeneca, BIAL Pharamaceuticals, Boehringer-Ingelheim, Boston Scientific, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD Pharmaceuticals, Merck-Serono, Merz, Novartis, Orion Pharma, Teva, University California Berkeley, and Zambon; and received royalties from Wiley Blackwell, Oxford University Press, and Cambridge University Press. MS received consultancy fees from Teva, Merz, Adamas, and Civitas; stock/stock options from Civitas and Adamas; and travel expenses from the International Parkinson and Movement Disorder Society. GD and LJ declare no competing interests. TGasser and IL-S declare no competing interests.",

year = "2016",

month = may,

day = "1",

doi = "10.1016/S1474-4422(16)00116-2",

language = "English",

volume = "15",

pages = "546--548",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Ltd.",

number = "6",

}

Postuma, RB, Berg, D, Adler, CH, Bloem, BR, Chan, P, Deuschl, G, Gasser, T, Goetz, CG, Halliday, G, Joseph, L, Lang, AE, Liepelt-Scarfone, I, Litvan, I, Marek, K, Oertel, W, Olanow, CW, Poewe, W & Stern, M 2016, 'The new definition and diagnostic criteria of Parkinson's disease', The Lancet Neurology, vol. 15, no. 6, pp. 546-548. https://doi.org/10.1016/S1474-4422(16)00116-2

TY - JOUR

T1 - The new definition and diagnostic criteria of Parkinson's disease

AU - Postuma, Ronald B.

AU - Berg, Daniela

AU - Adler, Charles H.

AU - Bloem, Bastiaan R.

AU - Chan, Piu

AU - Deuschl, Günther

AU - Gasser, Thomas

AU - Goetz, Christopher G.

AU - Halliday, Glenda

AU - Joseph, Lawrence

AU - Lang, Anthony E.

AU - Liepelt-Scarfone, Inga

AU - Litvan, Irene

AU - Marek, Kenneth

AU - Oertel, Wolfgang

AU - Olanow, C. Warren

AU - Poewe, Werner

AU - Stern, Matthew

N1 - Funding Information: DB received funds for consultancy/speaking from UCB pharma, Teva, Novartis, and Lundbeck; and grants from the Michael J Fox Foundation, Janssen Pharmaceuticals, the German Parkinsons' disease Association, Parkinson Fonds Deutschland, Teva, and the European Union. RBP received grants from the Fonds de la Recherche en Sante Quebec, the Canadian Institute of Health Research, the Parkinson Society of Canada, the Weston-Garfield Foundation, the Michael J Fox foundation, and the Webster Foundation; funding for consultancy from Biotie and Roche; and speaker fees from Novartis Canada and Teva Neurosciences. CHA has received research funding from Phytopharm, Avid Radiopharmaceuticals, the Michael J Fox Foundation, the National Institutes of Health, US Department of Defense, and the Arizona Biomedical Research Foundation; and consulting fees from Abbvie, Acadia, Allergan, Impax, Ipsen, Lily, Lundbeck, Merz, Novartis, Teva, and Xenoport. BRB received grant funding from the Netherlands Organization for Scientific Research, Prinses Beatrix Foundation, Stichting Parkinson Fonds, Michael J Fox Foundation, Parkinson Vereniging, and the National Parkinson Foundation; and consultancy/speaker fees from Danone, Zambon, Abbvie, and Teva. PC received grant support from the Ministry of Science and Technology of China. CGG received funds for consultancy from Acadia (Deborah Wood Associates), AstraZeneca, Avanir, Boston Scientific, Ceregene, Clearview, Health Advances, Chelsea Pharmaceuticals (Link Medical Communications), ICON Pricespective LLC, Med-IQ Educational Services, Neurocrine, Pfizer, Pricespective, Teva, and WPP Group Kantor Health LLC; royalties from Oxford University Press, Elsevier Publishers, Wolters Kluwer Health-Lippincott, and Wilkins and Wilkins; grant support from National Institutes of Health, Michael J Fox Foundation, and the Movement Disorders Society; travel support from Ceregene; and is a board member for Acadia and AstraZeneca. CGG directs the Rush Parkinson's Disease Research Center that receives support from the Parkinson's Disease Foundation; he directs the translation programme for the Movement Disorder Society Unified Parkinson's Disease Rating Scale and the Unified Dyskinesia Rating Scale and receives funds from the International Parkinson and Movement Disorder Society for this effort. GH has stock ownership in Cochlear and NIB Holdings; has received consultancy funds from the National Health and Research Council, has received royalties from Academic press, Elsevier, and Oxford University Press; and has grants from National Health and Research Council, Michael J Fox Foundation, Shake-it-Up Australia, Parkinson's NSW, and University of New South Wales. AEL received consultancy from Novartis, Teva, Abbott, Allon Therapeutics, Avanir Pharmaceuticals, Merck, Medtronic, AbbVie, Biogen Idec, Boehringer Ingelheim, NeuroPhage Pharmaceuticals, Centogene, Ceregene; expert testimony regarding welding rods; has grants/grants pending with Canadian Institutes of Health Research, Michael J Fox Foundation, National Parkinson Foundation, Brain Canada, W Garfield Weston Foundation, Parkinson Society Canada, Tourette Syndrome Association, Edmond J Safra Philanthropic Foundation, and Ontario Brain Institute; and has royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press. IL has served on advisory boards for Pfizer, Teva Neuroscience, Merz pharmaceuticals, Northera, Bristol-Myers Squibb, and has been a consultant for UCB pharma; she has received grants the National Institute of Health, the Parkinson Study Group, the Michael J Fox Foundation, CBD solutions-CurePSP, Teva Pharmaceuticals, and AVID Pharmaceuticals. KM received consultancy from Molecular Imaging, Pfizer, GE Healthcare, Merck, Lilly, Bristol-Myers Squibb, Piramal, Prothena, Roche, Oxford Biomedica, Lysosomal Therapeutic. WO is Senior Research Professor of the Charitable Hertie Foundation, Frankfurt/Main Germany. CWO received consultancy from Abbvie, Lilly/Medtronic, LUndbeck, Newron, Novartis, Teva, and Zambon, and owns stock in Clintrex, and has grant support from the Michael J Fox Foundation, the National Space Board Research Institute, and Zambon. WP received personal fees from Abbvie, Allergan, Astra Zeneca, BIAL Pharamaceuticals, Boehringer-Ingelheim, Boston Scientific, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD Pharmaceuticals, Merck-Serono, Merz, Novartis, Orion Pharma, Teva, University California Berkeley, and Zambon; and received royalties from Wiley Blackwell, Oxford University Press, and Cambridge University Press. MS received consultancy fees from Teva, Merz, Adamas, and Civitas; stock/stock options from Civitas and Adamas; and travel expenses from the International Parkinson and Movement Disorder Society. GD and LJ declare no competing interests. TGasser and IL-S declare no competing interests.

PY - 2016/5/1

Y1 - 2016/5/1

UR - http://www.scopus.com/inward/record.url?scp=84962873324&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(16)00116-2

DO - 10.1016/S1474-4422(16)00116-2

M3 - Letter

C2 - 27302120

AN - SCOPUS:84962873324

SN - 1474-4422

VL - 15

SP - 546

EP - 548

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 6

ER -